BRIEF-Chemocentryx says granted EU orphan drug designation for avacopan in treating patients with C3G
May 23 (Reuters) - Chemocentryx Inc (CCXI.O)
* Says granted EU orphan drug designation for avacopan in treatment of debilitating kidney disease C3 glomerulopathy
* Says plans to initiate a multi-center clinical endpoint study of avacopan for treatment of c3g in mid-2017
Source text for Eikon: Further company coverage: (CCXI.O)
